MRVI vs. DCPH, KROS, AMPH, TGTX, GERN, VERA, ARVN, RCKT, NAMS, and DYN
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Deciphera Pharmaceuticals (DCPH), Keros Therapeutics (KROS), Amphastar Pharmaceuticals (AMPH), TG Therapeutics (TGTX), Geron (GERN), Vera Therapeutics (VERA), Arvinas (ARVN), Rocket Pharmaceuticals (RCKT), NewAmsterdam Pharma (NAMS), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
Deciphera Pharmaceuticals (NASDAQ:DCPH) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends.
Deciphera Pharmaceuticals received 262 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. However, 67.44% of users gave Maravai LifeSciences an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
Maravai LifeSciences has higher revenue and earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 4.4% of Deciphera Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Deciphera Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.
Deciphera Pharmaceuticals currently has a consensus price target of $24.17, indicating a potential downside of 4.69%. Maravai LifeSciences has a consensus price target of $11.44, indicating a potential upside of 9.41%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Deciphera Pharmaceuticals.
Maravai LifeSciences has a net margin of -47.81% compared to Maravai LifeSciences' net margin of -119.33%. Deciphera Pharmaceuticals' return on equity of -4.17% beat Maravai LifeSciences' return on equity.
In the previous week, Maravai LifeSciences had 9 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 17 mentions for Maravai LifeSciences and 8 mentions for Deciphera Pharmaceuticals. Deciphera Pharmaceuticals' average media sentiment score of 0.24 beat Maravai LifeSciences' score of -0.05 indicating that Maravai LifeSciences is being referred to more favorably in the news media.
Summary
Maravai LifeSciences beats Deciphera Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
